• February 13, 2008

Acadia Pharmaceuticals, a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, has appointed John J. Kaiser as VP/strategic marketing and commercial development.

Kaiser joins Acadia from Eli Lilly & Co., where he held a variety of marketing and commercial management positions over a more than 25-year career.

At Eli Lily, he was responsible for establishing the business and brand strategy for Cymbalta, developing global market research in support of the successful launch of Zyprexa, and managing the global Prozac brand and associated marketing activities.

--Nina M. Lentini